Allosteric set to use quantum computing to target longevity and improve aging

New agreement between Allosteric Bioscience and Polaris Quantum Biotech paves the way for novel pharmaceuticals discovery.

Allosteric Bioscience, a company founded last year to integrate quantum computing and AI with biomedical sciences to create improved treatments for aging and longevity has signed a collaboration agreement with Polaris Quantum Biotech, a company at the forefront of quantum computing for drug discovery. Together, they are using advancements in quantum computing and AI for the development of novel pharmaceuticals.

Longevity.Technology: Quantum computing isn’t just fast computing – it’s computing jumped up to a whole other level (a quantum leap, if you will). Using quantum algorithms that exploit quantum entanglement these powerful machines can create massive multidimensional spaces to represent complex problems and therefore solve these problems faster, more efficiently and more elegantly than a standard, classical computer does.

Using qubits which have non-binary values (unlike the standard binary 0 and 1), quantum computers can analyse several options simultaneously, rather than just sequentially. The impact of QC on longevity drug discovery is set to be incredibly disruptive, as it will be able to compare millions of complicated molecules  at the same time, factoring in all the nuances of human biological systems. It is no wonder that biotechs and biopharmas are forging relationships with QC companies.

The focus of this agreement is a lead programme at Allosteric Bioscience that concentrates on improved aging, longevity and aging-related diseases which will be supported by an investment in Polarisqb. This joint program uses quantum computing (QC) and AI for creation of an inhibitor of a key protein involved in aging; this inhibitor could have numerous health benefits, as well as tapping into a multibillion-dollar market. Allosteric Bioscience is using its “QAB” platform for integrating QC, AI, genetics, genomics, system biology, epigenetics and proteomics, as well as two aging platforms: ALT (Aging Longevity Targets) and ALM (Aging Longevity Modulators).

Dr Shahar Keinan, CEO of Polarisqb said: “Quantum Computing technology is coming of age, allowing us to revolutionize drug discovery timelines, while improving the overall profile of the designed drugs. We are excited about the joint program with Allosteric tackling Aging and Longevity using Polarisqb’s Tachyon platform. The application of Quantum Computers to solving these complex questions is extraordinary [1].”

Dr Arthur P Bollon, President of Allosteric Bioscience, added: “The agreement between Allosteric Bioscience and Polarisqb represents an important milestone in implementing the Allosteric Bioscience strategy of integrating the Quantum Computer and advanced AI with Biomedical sciences for creation and development of advanced treatments for Improved Aging, Longevity and Aging related diseases [1].”

Polaris Quantum Biotech created the first drug discovery platform built on a quantum computer. Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, Polarisqb uses cloud, quantum computing and machine learning to process, evaluate and identify lead molecules 10,000 times faster than alternative solutions. These curated drug leads are taken to synthesis, testing and licensed to partners for development within months, rather than years. Information is available

Allosteric Bioscience was founded by Bruce Meyers, Arthur P Bollon PhD, and Peter Sordillo PhD MD; they all have years of expertise in the biotechnology industry as well as biomedical disciplines including genomics, epigenetics, systems biology, proteomics as well as oncology and quantum physics. Meyers and Bollon founded multiple biotechnology companies including Cytoclonal Pharmaceutics (Bollon served as Chairman and CEO) which merged to create OPKO Health, a NASDAQ company with a market cap of $2 billion.

Sordillo, who has a background in quantum information theory, is a leader in treating sarcomas and other cancers and managed over 50 clinical trials at leading institutions including Sloan Kettering Cancer Center.

Photograph: Christina Morillo/Pexels

No spam - just the good stuff

Subscribe to our newsletter